Here's Why You Should Add Surmodics Stock to Your Portfolio Now

Core Viewpoint - Surmodics, Inc. (SRDX) has shown strong performance in its latest quarter, with a narrower loss per share and sales exceeding market estimates, driven by its thrombectomy business [1][2]. Financial Performance - Surmodics reported a loss per share that was 51.9% narrower than market estimates and sales that beat estimates by 8.3% [1]. - The company achieved sales of $25.8 million in the Medical Device segment, reflecting a 22.4% increase year-over-year, primarily due to product sales from the Pounce thrombectomy device platform and SurVeil DCB [7]. - IVD sales improved by 7.9% to $7.5 million, driven by growth in distributed antigen and microarray slide/surface products [7]. Acquisition Details - Surmodics has entered into a definitive agreement to be acquired by GTCR for an estimated total equity valuation of $627 million, with shareholders set to receive $43.00 per share in cash [2][5]. - The current market price of SRDX shares is around $37, suggesting a potential gain of nearly 15% upon the deal's closure by the end of March [5]. Growth Prospects - Surmodics projects a remarkable 97.2% growth for fiscal 2025 and has consistently surpassed earnings estimates in the past four quarters, with an average surprise of 165.93% [3]. - The company is optimistic about leveraging its proprietary Pounce thrombectomy platform technology, with early results from a study presented at the TCT Symposium and FDA clearance for the Pounce XL Thrombectomy System [6]. Estimate Trends - The Zacks Consensus Estimate for Surmodics' earnings per share for fiscal 2025 has improved by 1 cent to 19 cents, with first-quarter fiscal 2025 revenue estimates at $33.5 million, indicating a 9.5% increase year-over-year [11].